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Abstract 
COVID 19 creates pandemic around the globe. This virus spread so rapidly and unfortunately till now there is no 
authentic treatment available. Based upon the trials various drugs were applied to control the disease. Different 
drugs found effective including hydroxychloroquine, dexamethasone, azithromycin and remdesivir. In current 
study 100 patients were participated. The presence of disease was confirmed by PCR based tests. Initials reports 
represent various abnormal range of WBC’s in patients. Most of them were symptomatic while few were 
asymptomatic. Gender wise COVID-19 mostly affected males rather than female gender. It was also found that 
older person were more susceptible than younger one.Effectiveness of the drugs shows there is need to do more 
work on following components to control the disease prevalence until a vaccine is discovered. 
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INTRODUCTION 
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus, 
more precisely beta family of coronaviruses type 2 (SARS-CoV-2) which primary occured in Wuhan, the capital 
city of Hubei provenance in China rapidly evolved into a global pandemic infecting million with no country 
spared.(1,2) A few new cases of atypical pneumonia were firstly detected by health authorities in Wuhan in late 
December.  Further research and genetic sequencing detected RNA virus which is part of the Coronavirus family, 
the same family of the virus which caused Severe Acute Respiratory Distress Syndrome known as SARS in 2003 
and Respiratory Syndrome of Middle East known as MERS in 2012. There is around 80% of genetic similarity 
between SARS-CoV and SARS-CoV-2 and occupying angiotensin-converting enzyme 2 (ACE2) receptors is 
considered for now the primary mechanism of how SARS-CoV-2 invades human cells. (1, 3) 
In spite of the that it is well confirmed that COVID-19 is first and foremost respiratory infection, 
considerable data emerge that COVID-19 should be also considered as a systemic infection, which involves 
multiple organs systems, such as cardiovascular, neurological, hematopoietic and gastrointestinal.(4) New 
evidence emerge that not only older people and those with comorbidities are at increased risk of serious 
complication or lethal outcome but younger population without significant underlying disease might also 
experience very serious complications such as disseminated vascular coagulopathy (DIC) or fulminant 
myocarditis.(4) 
A considerable piece of research shows that SARS-CoV-2 leads to “cytokine storm” causing activation of 
coagulation cascade causing thrombosis which compromises the blood supply of organs.(5) Haematological 
study of COVID-19 patients while patients are in incubation period (1-14 days) and at the early phase of 
COVID-19, shows that leukocytes and lymphocytes are usually normal or slightly reduced, while later on when 
clinical manifestations become more evident significant lymphopenia occurs. As lymphocytes express ACE2 
receptors on their surface, the possible mechanism of lymphopenia is that SARS-CoV-2 directly binds to these 
cells causing lysis of these cells.(5,6) In addition, the main feature of cytokine storm is increased concentrations 
of interleukins, mainly IL-2, IL-6, IL-7, TNF-α (tumor necrosis factor-alfa) which promote apoptosis of 
lymphocytes. Furthermore, cytokine storm might be related to atrophy of the spleen and lymphoid organs which 
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additionally has a negative impact turnover of lymphocytes.(5) Number of drugs until now have been tested 
against the virus. With large number of potential therapeutics, the goal is to test the efficiency and safety of these 
drugs. This study is a comparative analysis of Hydroxychloroquine, Azithromycin, Dexamethasone, Remdesivir 
and Tocilizumab on the outcome in patients affected with COVID-19. 
 
MATERIALS AND METHODS 
All the patients with lab-confirmed COVID-19 infection admitted to the emergency department of Aziz Bhatti 
Shaheed Hospital, (DHQ) Gujrat in province Punjab Pakistan between 2 April and 2 may 2020. Positive lab test 
for SARS-Cov-2 was depicted as a result of RT-PCR analysis. 
We have further divided the patients in sub categories of symptomatic, asymptomatic, male, and female and 
three age based groups.  
Data Collection 
On the basis of certain variables, patients were being evaluated. The recorded data comprises of the following: 
Age, Gender, complete blood count (CBC), renal function tests, Serum electrolytes, and Coagulation tests.  
Statistical Analysis 
The data was analysed by excel tool with sum and subtraction approach. The data is being illustrated in the pie 
charts. 
 
GENERAL CHARACTERIZATION OF THE PATIENTS 
In current study patients were analysed by PCR based diagnosis method. The study population comprises 
hundred patients having confirmed COVID-19. Out of these 100 patients 81% of a population were symptomatic 
while 19% asymptomatic. 
This study showed covid-19 suffering patients had 61% male while 39% were females. 
The median age of the patients ranges from 30 to 90 years old. 
 
Clinical Presentation of Patients 
The symptomatic patients have combination of symptoms varying in each patient. Fever was the most common 
and frequent symptom in patients. 17.2 % of total symptomatic patients had fever with no any other symptom. 
20% of symptomatic patient had shortness of breath, fever along with coughing while 13.58% reported to have 
sore throat along with shortness of breath and fever. 
11.11 % had fever along with cough and other details are mentioned in the table above. Fever, cough, sore 
throat, and shortness of breath were the main highlighted symptoms among covid-19 suffering patients. Other 
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Symptoms No. of Patient Percentage 
FEVER 14 17.2% 
COUGH 2 2.47% 
COUGH+BODY ACHE 2 2.47% 
COUGH+SOB 2 2.47% 
DRY COUGH 2 2.47% 
FEVER+COUGH 9 11.11% 
FEVER+DRYCOUGH 6 7.40% 
FEVER+MYALGIA 1 1.2% 
FEVER+SORE THROAT 11 13.58% 
SOB 4 4.93% 
SOB, ANOREXIA, FEVER, BODYACHE 7 8.64% 
SOB,COUGH  2 2.47% 
SOB, FEVER 9 11.11% 
SOB, FEVER+COUGH, ANOREXIA 2 2.47% 
SOB+ FEVER+COUGH 8 9.87% 
SOB+ARDS 1 1.2% 
 
 
Initial Report Results 
Initial reports of  patients represent that white blood cells count of patients of age group 30  was 3.9 to 7.9 In age 
group 30 to 60 years was 4.1 to 6.8 and in patients belonging to age group 60 to 90 years the value ranged from 
2.99 to 12.43. 
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Further details of their reports are given in the table below. 
 Age 30 Age 30 to 60 Age 60 to 90 
WBC(*10^9/l) 3.9 - 7.9 4.1 - 6.8 2.99 - 12.43 
Lymphocytes 1.41 - 3.41 1.90 - 3.19 0.7 - 1.54 
Granulocytes 1.5 - 6.13 1.6 - 6.10 1.49 - 11.34 
Platelets (*10^9/l) 108 - 314 120 - 155 108 - 173 
RBC (*10^12/l) 4.8 - 5.28 3.83 - 5.6 3.83 - 4.64 
Hb (g/dl) 9.1 - 13.3 8.9 - 13.9 7.4 - 14.1 
Na(mmol/l) 130 - 145 135 - 145 136 -147 
K(mmol/l) 3.9 – 5.9 3.10 - 6.5 3.11 - 6.8 
S/Creatinine (mg/dl) 0.7 - 1.3 0.8 - 1.3 0.9 - 1.8 
B/Urea (mg/dl) 22-41 23 - 84 20-202 
APTT(sec) 26-35 28-37 34-45 
PT (sec) 13 – 16 13 - 16 13 - 18 
INR 1.0 - 1.15 1.1 - 1.20 0.9 - 1.3 
Ca (mmol/l) 9.1 - 10.12 9.6 - 10.9 9.9-11 
Ph 2.1 - 8.5 2.1 - 8.3 2.1-9.2 
Age-Related Analysis  
To explore the impact of age with covid-19 the population was stratified into three major groups. Age group 30 
or less than 30. Second group ranges from 30 to 60 years old and third group patients ranges from 60 to 90 years 
old. 
Major signs and laboratory results were not much verified between age groups however where comparable 
the results indicated, old patients had a higher proportion covid-19 as compared to the younger patients. 
50% of the patients had age range 30 to 60 years while 30% were from age group 60 to 90 years and 20% of the 
study sample was less than 30 years old. Which clearly revealed that older age people are more susceptible to 
have covid-19 as compared to the younger ones. 
Treatment Details 
The treatment combination of HCQ, Azithromycin and Paracetamol was not given to a group of 30 years old 
patients while eight patients from group of 30 to 60 years old and four patients from age group 60-90 received 
this combination of drugs. 
Paracetamol+ Risek+ HCQ as treatment was given to two patients from age group 30 and four patients from 
age from 30 to 60. Amodil, Azithromycin and Surbex were given to one patient separately only, belonging to age 
group 60-90.  
The Combinations of lowplat+ Clexane, Aspirin+Risek, Acefyl+Fexet+Paracetamol, 
Dexamethasone+Paracetamol+Insulin, Diazepam+Dexamethasone, Aspirin+Risek were given to patients from 




Age 30 to 
60 
Age 60 to 
90 
PARACETAMOL 8 6 3 
PARACETAMOL+LOPRIN 0 1 0 
PARACETAMOL+OMEGA+REMDESIVIR+LOPRIN 0 1 0 
    
PARACETAMOL+RISEK+HYDROXYCHLOROQUINE 2 4 1 
PARACETAMOL+RISEK 1 1 0 
PARACETAMOL+RISEK +AZYTHROMYCIN+HEPAMERS 0 1 0 
PARACETAMOL+TONOFLEX+HEPAMERS 0 1 0 
PARACETAMOL+ACEFYL 0 2 0 
PARACETAMOL+ACEFYL+EZIDAY 0 1 0 
PARACETAMOL+EZIDAY+HCQ+RISEK 0 1 0 
PARACETAMOL+EZIDAY+RISEK 0 1 0 
PARACETAMOL+RISEK +CIPROFLOXACIN+GRAVID 0 1 0 
RISEK+MYRIN P FORTE 1 0 0 
RISEK+VANCOMYCIN 0 1 0 
SURBEX 0 0 1 
TOCILIZUMAB+DEXAMETHASONE 0 4 6 
ACEFYL+FEXET+PARACETAMOL 1 2 0 
AMODIL 0 1 0 
AZYTHROMYCIN 0 1 1 
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Age 30 to 
60 
Age 60 to 
90 
DEXAMETHASONE+ PARACETAMOL+INSULIN 0 0 1 
DIAZEPAM+ DEXAMETHASONE 0 0 1 
ASPIRIN+RISEK 0 0 1 
HCQ+FLAGEL+NOSPA+RISEK 1 0 0 
HCQ+PARACETAMOL 5 7 9 
HCQ+PARACETAMOL+AZYTHROMYCIN 0 8 4 
HCQ+RISEK+HYDRALINE 0 1 0 
HEPARIN+CLEXANE 0 1 0 
INSULIN+PARACETAMOL+RISEK 0 1 0 
LOPRIN 0 1 0 
LOWPLAT+CLEXANE 0 0 1 
MOXIFLOXACIN+AZYTHROMYCIN+PARACETAMOL+RISE
K 
0 1 1 
MULTIBIONTA 1 0 0 
After treatment with the above mentioned medications the reports of patients revealed that WBC of age 
group 30 ranges from 3.8 to 7.9. While the patients of age group 30-60 has WBC 2.95-9.57 and patients from 
age group 60 to 90 has WBC range 2.95-9.57. 
TREATMENT AGE WBC(*10^9/l) Lymphocytes Granulocytes Platelets Hb  
(g/dL) 
Na(mmol/l) K(mmol/l) S/Creatinine B/Urea APTT(sec) 
PARACETAMOL <=30 3.81-7.9 0.38-2.98 2.05-5.28 247-346 9.5-13.8 130-142 3.6-6.9 0.7-4.3 20-92 29-37  
30 to 60 3.95-8.54 0.38-4.24 1.50-7.97 119-480 8.9-13.8 130-142 3.2-6.9 0.6-4.3 21-92 23-36  
60 to 90 2.95-9.57 0.38-4.24 2.13-4.66 119-447 8.9-13.2 130-142 3.8-6.9 0.7-4.3 20-92 28-36 
PARACETAMOL+RISEK+HCQ <=30 2.24-6.21 0.75-1.54 3.38-4.11 108-253 8.8-11.8 135-136 4.3-4.8 0.8-1.2 31-202 25-34 
  30 to 60 2.24-6.97 0.75-2.4 2.18-4.11 108-259 8.8-15.2 135-141 4.3-4.8 0.8-1.2 24-202 31-33 
 60-90 12.43 0.7 11.34 141 11.7 145 6.2 1.4 38 30 
PARACETAMOL+RISEK <=30 16.2 2.2 13.7 198 14.1 137 3.9 1.1 19 31  
30 to 60 7.83 1.80 5.05 253 13.7 140 3.8 0.9 20 32 
RISEK+MYRIN P FORTE <=30 19.01 0.93 17.51 104 11.9 149 3.4 1 23 36 
AMODIL 30 to 60 13.49 0.59 12.28 259 12.1 139 5.6 1.1 47 39 
AZYTHROMYCIN 30 to 60 28.3 2.1 17 372 11 144 3.1 0.9 53 17 
  60 to 90 14.8 1 13.28 241 13.1 123 4.7 1.4 76 38 
PARACETAMOL +FEXET+ACEFYL <=30 5.84 1.51 2.91 347 13.2 137 6.2 1.5 46 33  
30 to 60 4.79-9.57 2.71-3.76 1.68-4.86 215-409 11.6-14 135-142 4.2-4.3 1.1-1.3 31-34 30-33 
DEXAMETHASONE+PARACETAMOL 
+INSULIN 
60 to 90 16.2 2.1 7.3 259 8.09 123 3.7 1.5 47 41 
DIAZEPAM+DEXAMETHASONE 60 to 90 18.1 0.82 7.9 355 8.5 130 4.8 1.7 78 49 
ASPIRIN+RISEK 60 to 90 14.85 1.51 6.1 223 15.7 138 5.8 1.6 28 55 
HCQ+FLAGEL+NOSPA+RISEK <=30 3.83 1.55 2.99 337 13.0 140 4.0 0.9 26 32 
HCQ+PARACETAMOL  <=30 3.81-7.6 3.8-2.86 2.05-4.81 347-426 10.5-
13.6 
132-141 3.5-6.8 0.7-1.8 24-42 29-35 
 30-60 3.85-9.25 0.31-4.21 1.25-7.91 260-496 10.5-
14.1 
132-143 3.7-6.9 0.8-1.9 26-49 28-36 
 60-90 4.79-8.12 2.16-3.02 1.67-3.96 385-409 12.9-
14.1 
133-143 4.2-4.7 1.1-1.5 37-52 32-45 
HCQ+PARACETAMOL 
+AZYTHROMYCIN 
30 to 60 2.36-7.94 0.65-4.12 3.10-4.26 245-426 11.5-
13.9 
134-137 3.9-4.2 0.9-1.2 22-49 29-35 
 60 to 90 7.4-9.5 2.16-3.01 1.59-3.20 247-358 9.5-12.5 130-143 3.6-6.9 0.7-4.8 36-52 31-47 
HCQ+RISEK+HYDRALINE 30 to 60 6.78 2.13 4.79 314 13.8 137 4.0 1.1 27 37 
HEPARIN+CLEXANE 30 to 60 6.26 0.63 5.26 299 7.4 147 3.8 1.6 32 58 
INSULIN+PARACETAMOL+RISEK 30 to 60 4.23 1.88 2.07 248 11.6 137 4.8 1.7 22 30 
LOPRIN 30 to 60 12.31 0.63 11.63 358 8.3 140 4.1 1.6 43 64 
LOWPLAT+CLEXANE 60 to 90 10.3 1.2 12.8 296 15.5 138 3.4 1.9 67 98 
MOXIFLOXACIN+AZYTHROMYCIN 
+PARACETAMOL +RISEK  
30 to 60 4.52 0.65 3.02 554 8.2 141 3.2 0.6 20 34 
 60-90 4,75 1.1 2.20 396 12.5 139 3.9 0.6 41 39 
MULTIBIONTA <=30 18.03 0.5 17.27 83 10.9 150 4.1 1.6 68 122 
PARACETAMOL +LOPRIN 30 to 60 2.99 0.71 1.49 173 7.4 137 3.8 1.2 22 31 
PARACETAMOL 
+OMEGA+REMDESIVIR+LOPRIN 
30 to 60 3.48 0.06 1.79 328 10.7 141 4.9 0.9 47 32 
PARACETAMOL +RISEK+MONTIKA 60 to 90 12.43 0.7 11.34 141 11.7 145 6.2 1.4 38 30 
PARACETAMOL +RISEK 
+AZYTHROMYCIN+HEPAMERS 
30 to 60 6.01 2.59 
 
318 14.2 141 3.5 1.1 28 30 
PARACETAMOL 
+TONOFLEX+HEPAMERS 
30 to 60 5.21 1.29 3.49 173 13.5 139 3.7 0.9 20 30 
PARACETAMOL+ACEFYL 30 to 60 2.24-9.57 0.75-4.24 3.38-4.66 253-447 10.5-
11.8 
135-136 3.9-4.3 0.8-0.9 31-41 31-32 
PARACETAMOL+ACEFYL+EZIDAY 30 to 60 6.97 1.85 2.18 259 15.2 140 4.6 1 24 31 
PARACETAMOL+EZIDAY+HCQ+RISEK 30 to 60 3.48 0.06 1.79 328 10.7 141 4.9 0.9 47 32 
PARACETAMOL+EZIDAY+RISEK 30 to 60 4.52 0.65 3.02 554 8.2 141 3.2 0.6 20 34 
PARACETAMOL+RISEK 
+CIPROFLOXACIN+GRAVID 
30 to 60 6.21 1.54 4.11 108 8.8 136 4.8 1.2 45 31 
TOCILIZUMAB+DEXAMETHASONE 30-60 3.142-8.65 0.34-4.10 1.49-7.27 220-475 8.6-13.6 130-143 3.2-6.8 0.6-4.2 22-62 28-36 
 60-90 3.84-6.75 0.75-4.21 3.39-4.52 245-401 10.6-
12.3 
134-137 4.1-4.3 0.8-0.9 31-45 27-36 
RISEK+VANCOMYCIN 30 to 60 7.21 0.86 5.86 274 9.2 144 3.8 0.7 45 38 
SURBEX 60 to 90 13.45 0.97 12.13 281 12.5 135 4.2 1.1 39 65 
 
Discussion 
The current study involved the hundred patients suffering from covid-19 in Gujrat, Punjab Pakistan. The clinical 
signs and symptoms of patients indicated that Age, Gender and Medication were the most common factors in the 
progression of disease. 
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In this study the median age of patients was 30-60  years that was in line with the study conducted in China 
where median age was reported 65.8 years old.(7) These results indicated that the progression in age is a major 
factor in occurrence of covid-19. As according to Mei J, et al there is greater intensity of prevailing this disease 
in males as compared to females. Our results showed the same trend of results that male persons are more 
susceptible to get infected with SARS-coV2 infection than females (8) The reason behind this phenomenon is 
not fully explained yet. Fever was the most common symptom observed in patients suffering from covid-19. 
(9,10) The major supportive therapy was given to the patients as a combination of drugs that are  mentioned 
above. The major effective combination of drugs include: Azithromycin, Paracetamol, Hydroxychloroquine, 
Remdesivir, Tocilizumab, and Dexamethasone. The usage of this combination of drugs proved to give a speedy 
effect as a recovery of COVID effected patients. Moreover the positive effect of these drugs was clearly evident 
in the laboratory reports of the effected patients.  
 
Conclusion 
Most of the patients being severely affected with covid-19 infection were male with the age more than 60 years 
and they presented with certain symptoms as mentioned above. Among all of these the fever, cough and 
shortness of breath were most common symptoms in these patients. The most effective therapeutic drugs against 
the majorly effected patients of COVID-19 were PARACETAMOL, TOCILIZUMAB, AZITHROMYCIN, 
HYDROCHLOROQUINE, and REMDESIVIR.  
Gender Percentage No. of Pt. 
Male 61% 61 
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